Click here to download the SSM9 preliminary program
SSM9 Program
SUNDAY, July 2nd, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
15:00 – 16:00 Registration
16:00 – 16:30 OFFICIAL OPENING – 9th Summer School on Medicines (SSM9)
Jordi Fàbrega, Director of Business Development Area at Biocat, Chairman.
Ignasi Belda, General Director at Barcelona Science Park
Pierre Cordelier, Professor and Researcher at INSERM U1037, Toulouse Oncopole & Université Paul Sabatier III, Toulouse, Chairman
Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec, Chairman
Rémy Poupot, Professor and researcher at INSERM, Université Paul Sabatier, Toulouse
Jordi Quintana, SSM9 Scientific Committee, Chairman
16:30 – 18:30 Keynote Sessions
Keynote Session 1 (KNS1):
Developing a new model of partnership between academia and the pharmaceutical industry; a focus on G protein-coupled receptor as an evolving drug target family
Michel Bouvier, Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Québec
Keynote Session 2 (KNS2):
Swimming with the sharks (Oryzon’s quest for drugs to treat cancer and neurodegeneration)
Jordi Salas, Senior Project Leader at Oryzon
18:30 – 20:30 Welcome Reception at Clúster Terrace / Barcelona Science Park (PCB)
MONDAY, July 3rd, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
SESSION I: DRUG R&D, AN OVERVIEW FROM IDEA TO MARKET
Chairperson: Denis deBlois, Jordi Quintana
09:00 – 10:30 (S1) Drug Discovery Overview
Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec
10:30 – 11:00 Health Break
11:00 – 12:30 (S2) Drug Development Overview
Manuel Merlos, Director of Pharmacology at Esteve R+D
12:30 – 13:30 (S3) Beyont the Pill 1 (Precision Medicine / Genomics)
Ivo Gut, Director of Centre for Genomic Regulation (CRG)
13:30 – 14:30 Lunch (PCB Restaurant)
14:30 – 15:00 Visit to PCB facilities
SESSION II: DRUG DISCOVERY
Chairperson: Jordi Quintana
15:00 – 15:45 (S4) Chemical Biology / Drug Design / Systems Pharmacology
Jordi Mestres, Head of the Systems Pharmacology Group at Hospital del Mar
Medical Research Institute (IMIM), University Pompeu Fabra
15:45 – 16:30 (S5) Medicinal Chemistry
Carme Almansa, Chemistry Director at Esteve
16:30 – 17:00 Health Break
17:00 – 17:45 (S6) New classes of biological drugs: Cell and gene therapy products
Pierre Cordelier, Professor and Researcher at INSERM U1037, Toulouse Oncopole & Université Paul Sabatier, Toulouse
17:45 – 18:30 Plenary discussion with speakers
TUESDAY, July 4th, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
SESSION III: FROM DRUG DISCOVERY TO EARLY CLINICAL DEVELOPMENT (I)
Chairperson: Denis deBlois, Pierre Cordelier
09:00 – 9:45 (S7) ADME (Pharmacokinetics / Pharmacodynamics)
Ismael Zamora, Associate Professor at Universitat Pompeu Fabra, CEO of Lead Molecular Design, S.L
9:45 – 10:30 (S8) Drug Delivery & Pharmaceutical Development
PierAndrea Esposito, Associate Director of SiTec PharmaBio
10:30 – 11:00 Health Break
11:00 – 11:45 (S9) Drug Discovery of dendrimers: From idea to optimization
Cédric-Olivier Turrin, Laboratoire de Chimie de Coordination, CNRS, Toulouse
Rémy Poupot, Professor at University of Toulouse, INSERM
11:45 – 12:30 (S10) Drug development of dendrimers: Animal models, preclinical development, computation
Cédric-Olivier Turrin, Laboratoire de Chimie de Coordination, CNRS, Toulouse
Rémy Poupot, Professor at University of Toulouse, INSERM
12:30 – 13:30 (S11) Beyond the Pill 2 (Multifunctional nanovesicles for drug delivery applications)
Jaume Veciana, Head Department at ICMAB
13:30 – 14:30 Lunch (PCB Restaurant)
SESSION IV: CASE STUDY IN DRUG DISCOVERY AND DEVELOPMENT
Chairperson: Denis deBlois, Rémy Poupot, Pierre Cordelier
14:30 – 15:00 Case presentation and outline of challenges
15:00 – 16:00 Group session
16:00 – 16:30 Health break
16:30 – 18:00 Each team reports / General discussion
WEDNESDAY, July 5th, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
SESSION V: FROM DRUG DISCOVERY TO EARLY CLINICAL DEVELOPMENT (II)
Chairperson: Jordi Quintana
09:00 – 09:45 (S12) Public-private partnerships. A view from the pharmaceutical industry
Andrés Fernández, Director at Ferrer Advanced Biotherapeutics
09:45 – 10:30 (S13) Toxicology / Preclinical Safety
Antonio Guzmán, Head of the Toxicology Department at Esteve
10:30 – 11:00 Health Break
11:00 – 11:45 (S14) Chemical Process Development and Manufacturing of an API
Ramón Berenguer, Process R&D Director at Esteve Química
11:45 – 12:30 (S15) Learning and confirming trials
Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec
12:30 – 13:30 SSM9 Students Presentations
13:30 – 14:30 Lunch (PCB Restaurant)
14:30 – 15:30 Visit to CNAG-CRG (National Center for Genomic Analysis) (PCB)
15:30 – 17:00 Visit to Esteve Preclinical R+D laboratories (PCB)
THURSDAY, July 6th, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
SESSION VI: CLINICAL DEVELOPMENT / REGULATORY
Chairperson: Denis deBlois
9.00 – 9:45 (S16) Clinical Phases
Anne Leselbaum, Medical Consultant at Clinical Drug Development
9:45 – 10:30 (S17) Benefit / Risk Assessment / Pharmacovigilance
Alice Dragomir, Assistant Professor at Research Institute of McGill University Health Center
10:30 – 11:00 Health break
11:00 – 11:45 (S18) Pharmaco-economics in drug development
Oriol Solà-Morales, CEO and Founder of HITT – Health Innovation Technology Transfer, SAGESSA, Universitat Internacional de Catalunya (UIC)
11:45 – 12:30 (S19) Regulatory Development Strategy
Xavier Luria, Senior Consultant at Drug Development and Regulation
12:30 – 13:30 (S20) Beyond the Pill 3 (Medical devices: from idea to first sales – an entrepreneur’s point of view)
Markus Wilhelms,CEO & Co-Founder at usMIMA & MOWOOT
13:30 – 14:30 Lunch ( PCB Restaurant)
14:30 – 15:15 (S21) New models in Tech Transfer: Spherium Biomed
Pedro Grima, Senior Project Manager at Spherium Biomed
15:15 – 16:00 (S22) Ideas-Team-Commitment, three pillars of entrepreneurial success
Albert Palomer, CEO at ABAC Therapeutics
16:00 – 16:45 (S23) The role and value of pharmaceutical marketing.
Laurence Mickalonis, President and Senior Partner at Life Science Praxis
16:45 – 17:45 SSM9 Students Presentations
FRIDAY, July 7th, 2017
Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)
SESSION VII: PHARMACO ECONOMICS & INTELLECTUAL PROPERTY
Chairperson: Jordi Fàbrega
09:00 – 09:45 (S24) IP Protection in the Pharmaceutical Industry
Enric Carbonell, Partner at ABG Patents
9:45 – 10:30 (S25) Market access
Nerea Alonso, Partner at AEC Consultants
10:30 – 11:00 Health Break
SESSION VIII: PUBLIC-PRIVATE / CONTRACT RESEARCH & BUSINESS DEVELOPMENT
Chairperson: Jordi Fàbrega
11:00 – 11:45 (S26) Contract Research & Contract Business Development
Daniel González, Vice-President Business Development at Trifermed
11:45 – 12.30 (S27) Patients empowerment. Their role in the Drug Discovery & Development
Marta Príncep, CEO of Fundació GAEM
12:30 – 13:30 (S28) Beyond the Pill 4 (New technologies: Photopharmacology)
Amadeu Llebaria, research scientist at CSIC
13:30 – 15:00 Lunch (PCB Restaurant)
SESSION IX: CLOSING SESSION
Chairperson: Jordi Fàbrega
15:00 – 15:45 Closing Keynote Sesion: From idea to clinical trials
Raúl Insa, CEO of SOM Biotech
15:45 – 16:15 SSM9 Evaluation / Final Discussion
16:15 – 17:00 SSM9 closing comments and overture towards SSM10 in São Paulo and SSM11 in Montréal
9th Summer School on Medicines 